The North America Veterinary oncology Market would witness market growth of 12.4% CAGR during the forecast period (2020-2026).
Veterinary radiation oncology continues to advance with the introduction of emerging technology, procedures, and guidelines while growing patient outcome knowledge. They do face gaps in expertise and require randomized clinical trials to evaluate true results for clinicians, prognostic factors, dose tolerances, and toxicity.
In animals, lymphoma (lymphosarcoma) is a type of cancer characterized by the proliferation of malignant lymphocytes in solid organs such as the lymph nodes, bone marrow, liver, and spleen. The disorder can also occur in the gastrointestinal tract of the body, skin, and. Close supervision of dogs receiving chemotherapy is necessary because of the high risk of recurrence and resulting problems. The same refers to dogs who have reached remission and have ceased treatment. Disease and remission/recurrence control is normally done by peripheral lymph node palpation. This detects significant changes in peripheral lymph nodes. Some of the blood testing used to detect lymphoma often provide more objectivity and provide an early warning of an animal coming out of remission.
Veterinary cancer treatments aim at eradicating the cancer cells that are present in pets. Based on the type of cancer, stage, and nature of the disease, the veterinarian recommends different treatments such as targeted therapy and combination therapy or chemotherapy. Researchers’ ongoing research efforts for the development of new formulations and therapies are expected to stimulate the growth of the global veterinary oncology market. With the advent of tailored treatments, conventional cancer therapy can be revolutionized.
Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.
Scope of the Study
Market Segmentation:
By Animal Type

  • Canine and
  • Feline


By Therapy

  • Chemotherapy
  • Radiology
  • Surgery
  • Immunotherapy and
  • Others


By Cancer Type

  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer and
  • Others


By Country

  • US
  • Canada
  • Mexico
  • Rest of North America


Companies Profiled

  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
  • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
  • Nippon Zenyaku Kogyo Co., Ltd.


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free